ArticleCancer reports (Hoboken, N.J.)2025
Low Cholinesterase Is a Potential Poor Prognostic Factor in Colorectal Cancer Presenting With Tumor Markers Negative.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study.Journal of clinical medicine · 2026Article
- Genetic and Epigenetic Mechanisms in Serrated Adenocarcinomas and Classical Colorectal Carcinomas: An In Silico Study.Current issues in molecular biology · 2026Article
- Impact of the COVID-19 Pandemic on Colorectal Cancer Surgery: Surgical Outcomes and Tumor Characteristics in a Multicenter Retrospective Cohort.Journal of clinical medicine · 2025Article
- Low Cholinesterase Is a Potential Poor Prognostic Factor in Colorectal Cancer Presenting With Tumor Markers Negative.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common malignant tumor in the world and has the second highest mortality rate. Tumor markers are proteins used to diagnose and monitor cancer. Serum cholinesterase (CHE) is a nutritional indicator indicating the liver''s ability to synthesize proteins and is a predictor of CRC. Butyrylcholinesterase (BCHE), a CHE enzyme encoded by the BCHE gene, is synthesized by the liver and released into the serum.
objectiveTo study the association between CHE and survival prognosis in CRC with tumor markers negative (TMN). The relationship between the BCHE gene and immune cell infiltration was also explored.
methodsThe clinical data of patients with CRC were collected. The data included tumor markers and biochemical indicators. Patients were divided into different groups for prognosis analysis. CHE levels were used as the cutoff for classification. Further analysis was conducted on the all-TMN group. CHE was found to be correlated with survival prognosis. This study also analyzed BCHE gene expression in cancer and normal tissues. A correlation analysis was conducted with other factors.
results(1) Among 1140 patients who met the criteria, the TMN group (n = 369) had a higher survival rate (89.7%) than the TMP group (n = 771, 83.3%; p = 0.035). (2) Among 1140 CHE, the low cholinesterase (CHE
conclusionIn CRC with TMN, CHE is an independent detrimental prognostic factor. BCHE may serve as a biomarker for CRC to help predict its prognosis and may have an essential impact on immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.